Brian C. Broderick’s Denali Therapeutics DNLI Stock Holding History

Brian C. Broderick’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,000	Closed	-$202K	–	79
2021 Q3	$202K	Hold	4,000	–	–	0.05%	79
2021 Q2	$314K	Hold	4,000	–	–	0.08%	66
2021 Q1	$228K	Hold	4,000	–	–	0.07%	73
2020 Q4	$335K	Sell	4,000 -52,000	-93%	-$3.14M	0.1%	60
2020 Q3	$2.01M	Sell	56,000 -28,507	-34%	-$859K	0.64%	44
2020 Q2	$2.04M	Buy	+84,507	New	+$1.99M	0.68%	44

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Brian C. Broderick's DNLI Position: Q4 2021 in Review

Brian C. Broderick sold out of Denali Therapeutics (DNLI) in Q4 2021, closing a stake of 4,000 shares — an estimated $202K sold.

Brian C. Broderick first reported a position in DNLI in Q2 2020 and held it in 6 quarters. The position peaked at $2.04M in Q2 2020. 213 funds tracked by Wall St. Rank hold DNLI as of Q4 2021.

Brian C. Broderick reported no remaining Denali Therapeutics position as of Q4 2021 after selling out during the quarter.
Brian C. Broderick sold 4,000 Denali Therapeutics shares in Q4 2021, an estimated $202K.
Brian C. Broderick first reported a position in Denali Therapeutics in Q2 2020 and held it in 6 quarters.
Brian C. Broderick's Denali Therapeutics position peaked at $2.04M in Q2 2020.
213 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2021.

Based on Brian C. Broderick's 13F filing for Q4 2021, filed 8 Feb 2022.